CFL-120

Cat. No.:	HY-W041315
CAS No.:	18711-15-4
Molecular Formula:	$C_8H_3Cl_2NO_2$
Molecular Weight:	216.02
Target:	Ras
Pathway:	GPCR/G Protein; MAPK/ERK Pathway
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



BIOLOGICAL ACTIVITY

Description	CFL-120 is a potent $KRas^{G12C}$ inhibitor. CFL-120 shows an antiproliferative effect. CFL-120 shows anticancer activity. CFL-120 has the potential for the research of lung cancer[1].
IC_{50} & Target	KRAS(G12C)
In Vitro	CFL-120 (72 h) shows an antiproliferative effect with IC_{50}s of 11.0, 23.6, 13.7, 16.9, 44.4, 14.8, 38.0, 30.0, 13.1, 9.8, 47.9, 24.4, 42.7 μM for H1792, SW1573, MiaPaca2, H358, A549, SW480, PANC-1, LCLC-103H, BxPC3, HCA-7, MRC-5, HUVEC-TERT, CCD-986Sk cells, respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	CFL-120 (5 mg/kg, 5 treatments; 15 mg/kg, 5 treatments; 30 mg/kg, 3 treatments; i.p.) reduces tumor growth in subcutaneous H1792 (KRasG12C mutant) and LCLC-103H (KRasWT) human lung cancer-bearing mice[1]. Pharmacokinetic Parameters of CFL-120 in NOD-SCID female mice[1].

PK parameters	CFL-137
C_{max} (ng/mL)	337 ± 123
T_{max} (h)	0.25
AUC_t (ng/mL*h)	169 ± 56
$t_{1/2}$ (h)	4.4 ± 0.6
V_d (mL)	12,096 ± 4000
CL(mL/h)	1895 ± 539

NOD-SCID female mice, 15 mg/kg IP[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD/SCID female mice (KRasWT (LCLC-103H) or KRasG12C (H1792) tumors)[1]
Dosage:	5 mg/kg, 5 treatments; 15 mg/kg, 5 treatments; 30 mg/kg, 3 treatments
Administration:	I.p.
Result:	Reduced tumor growth compared to the control group in KRasG12C mutated model for 35.8%.

REFERENCES

[1]. Orgován Z, et al. Covalent fragment mapping of KRasG12C revealed novel chemotypes with in vivo potency. Eur J Med Chem. 2023 Mar 15;250:115212.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA